• हिन्दी
  • ગુજરાતી
  • বাংলা
  • తెలుగు
  • मराठी
  • ಕನ್ನಡ
  • money9
  • Insurance
  • Saving
  • Loan
  • Mutual Funds
  • Investment
  • Breaking Briefs
downloadDownload The App
Close
  • Home
  • Videos
  • Podcast
  • Banking
  • Bulletin
  • Gold
  • Healthcare
  • Real Estate
  • Tax
  • Travel
  • Breaking Briefs
  • Insurance
  • Savings
  • Loan
  • Crypto
  • Investment
  • Mutual Funds
  • Real Estate
  • Tax
  • Exclusive
  • Home / Covid Update }

COVID-19: Antibodies may last from days to years, depending on severity, says study

Recovered patients with low levels of neutralising antibodies may still be protected from reinfection if they have robust immunity in the form of the body's T cells, according to a study

  • Press Trust of India
  • Last Updated : March 24, 2021, 13:44 IST
  • Follow
COVID-19: Antibodies may last from days to years, depending on severity, says study
Cumulative vaccine doses administered so far have reached 42.78 crores.
  • Follow

Singapore: Antibodies against the novel coronavirus wane at different rates, lasting for mere days in some individuals, while persisting in others for decades, according to a new study which says COVID-19 severity could be a deciding factor in having longer-lasting protection against reinfection.

The research, published in The Lancet Microbe journal, noted that recovered patients with low levels of neutralising antibodies may still be protected from reinfection if they have robust immunity in the form of the body’s T cells.

In the study, scientists, including those from Duke-NUS Medical School in Singapore, followed 164 COVID-19 patients for six to nine months, analysing their blood for neutralising antibodies against the SARS-CoV-2 virus, their T cells and immune system signalling molecules. They then used this information to train a machine-learning algorithm to predict the trajectories of people’s neutralising antibodies over time.

Based on the analysis, the researchers categorised people into five groups depending on how long their antibodies lasted.

The first group, they said, included those who never developed detectable neutralising antibodies—also called the ‘negative’ group—and comprised 11.6% of the patients in the study.

The ‘rapid waning’ group, which included 26.8% of the patients, had varying early levels of antibodies that waned quickly, the scientists said. According to the researchers, the ‘slow waning’ group, which included 29% of the participants, tested mostly positive for antibodies at six months.

The ‘persistent’ group, comprising 31.7% of the individuals, showed little change in their antibody levels up to 180 days and, they said, adding that the ‘delayed response’ group (1.8%) showed a significant rise in neutralising antibodies during late convalescence.

“The key message from this study is that the longevity of functional neutralising antibodies against SARS-CoV-2 can vary greatly and it is important to monitor this at an individual level,” said Professor Wang Linfa, from Duke-NUS’ Emerging Infectious Diseases (EID) Programme, a corresponding author of the study.

“This work may have implications for immunity longevity after vaccination, which will be part of our follow-up studies,” Linfa added.

According to the study, patients, including those from the ‘negative group’, displayed sustained T-cell immunity six months after initial infection, indicating that individuals may still be protected if they have a robust T-cell immunity when the neutralising antibody level is low.

“Our study examines neutralising antibodies which are important in protection from COVID-19. We found that antibodies against SARS-CoV-2 wane in different people at different rates,” said study corresponding author David Lye from the National Centre for Infectious Diseases (NCID), Singapore.

Based on the results, the scientists emphasised the importance of public health and social measures in the ongoing pandemic outbreak response. They said the presence of T-cell immunity provides hope of longer-term protection, adding that more studies are needed to confirm the findings.

Since antibodies wane faster in some individuals, the scientists believe re-infection may occur in subsequent waves of infection. They said if immunity provided via vaccinations also wanes like naturally-produced antibodies, annual vaccine administration could be necessary to prevent future outbreaks of COVID-19.

However, the researchers said further research is needed to clarify the findings as vaccine programmes are rolled out across the world.

Published March 24, 2021, 13:44 IST

Download Money9 App for the latest updates on Personal Finance.

  • Antibodies
  • Coronavirus
  • Covid-19

Related

  • Covid first wave led to increase in antibiotic misuse in India: Study
  • Centre rushes teams to six states reporting a high number of Covid cases
  • Covid-19: India records 46,617 new cases; national recovery rate crosses 97%
  • India’s medical infrastructure well prepared to deal with possible third Covid wave, says FM
  • Karnataka makes RT-PCR negative report, vaccine certificate must for Kerala travellers
  • National Doctors’ Day: Over 1500 doctors sacrificed their lives in fight against Covid-19

Latest

  • 1. How Amazon, Flipkart use dark patterns to lure you!
  • 2. Don't Get Swamped By This!
  • 3. How can you find whether you have malware in your device?
  • 4. This Deed Can Give Peace of Mind!
  • 5. How much overvalued is Nifty right now?

Trending 9

  • What's happening on India's employment front?
    1 What’s happening on India’s employment front?
    More than 80% of the hired frontline workers held either a graduation degree, or at least a high school diploma. Nevertheless, the need for upskilling in this cohort was immense, with sign-ups for such courses jumping by 194% between FY22 and FY23.
    Exclusive
    alternate

    Read

  • 2How multicap is different from multi-asset allocation fund
    Investment
    read_icon

    Read

  • 3How to prepare portfolio of shares of food and beverage business during festive season?
    Sports
    read_icon

    Read

  • 4MGL, Hindalco among long term picks of Gaurang Shah
    Stocks
    read_icon

    Read

  • 5Investment Reflections from Lord Ganesha
    Investment
    read_icon

    Read

  • 6Premium listing of EMS
    Exclusive
    read_icon

    Read

  • 7What is the ideal way to ensure children don’t get into property dispute!
    Property
    read_icon

    Read

  • 8Govt bonds in JP Morgan’s bond index could also support Indian currency
    Economy
    read_icon

    Read

  • 9Kotak Mahindra Bank hikes fixed deposit interest rates
    Banking
    read_icon

    Read

Exclusive

Frequent train traveller? Rules you need to know
Frequent train traveller? Rules you need to know
Exclusive
read_icon

Read

No credit card? Pay shopping EMIs via debit cards
Exclusive
read_icon

Read

Investing in Inflation: How to Grow Your Wealth Amidst Economic Challenges
Exclusive
read_icon

Read

Debt Mutual Fund- A stable and Steady investment choice
Mutual Funds
read_icon

Read

The dark alleys on online shopping!
Cyber security
read_icon

Read

  • Trending Stories

  • How should you utilise bonus of your participating insurance policy?
  • How to prepare portfolio of shares of food and beverage business during festive season?
  • Can you withdraw money from PPF before 15 years?
  • Sebi extends deadline for nominations
  • Can you withdraw money from PPF before 15 years?
  • TV9 Sites

  • TV9 Hindi
  • TV9Telugu.com
  • TV9 Marathi
  • TV9 Gujarati
  • TV9 Kannada
  • TV9 Bangla
  • News9 Live
  • Trends9
  • Money9 Sites

  • Money9 Hindi
  • Money9 English
  • Money9 Marathi
  • Money9 Telugu
  • Money9 Gujarati
  • Money9 Kannada
  • Money9 Bangla
  • Topics

  • Insurance
  • Savings
  • Loan
  • Stocks
  • Mutual Funds
  • Real Estate
  • Tax
  • Crypto
  • Exclusive
  • Follow us

  • FaceBook
  • Twitter
  • Youtube
  • Instagram
  • Linkedin
  • Download App

  • play_store
  • App_store
  • Contact Us
  • About Us
  • Advertise With Us
  • Privacy & Cookies Notice
  • Complaint Redressal
  • Copyright © 2023 Money9. All rights reserved.
  • share
  • Facebook
  • Twitter
  • Whatsapp
  • LinkedIn
  • Telegram
close